Preventive cardiology

Current Opinion in Cardiology

Volumn 14, Issue 5, 1999, Pages 382-391

  Foody, Jo Anne Micale ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CANDESARTAN; CAPTOPRIL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FELODIPINE; GEMFIBROZIL; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROXITHROMYCIN; SIMVASTATIN; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW;

EID: 0032850280     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199909000-00006     Document Type: Review

References (33)

1. Scandinavian Simvastatin Survival Study group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1289.
2. Pfeffer MA, Sacks FM, Moye LA, et al.: Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995, 76:98C-106C.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357. This major, randomized, controlled, secondary prevention clinical trial of pravastatin versus placebo extends the benefit of cholesterol reduction to those with average risk for recurrent CHD. The trial includes a significant number of women and minorities. In addition, the study shows a significant reduction in cerebrovascular events
4. Design features and baseline characteristics of the LIPID (Long Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995, 76:474-479.
5. Downs JR, Beere PA, Whitney E, et al.: Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 1997, 80:287-293.
6. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622. A total of 6,605 individuals (5,608 men and 997 women) were studied who were free of any evidence of CAD and had the following values: total cholesterol between 180 and 264 mg/dL; LDL-C between 130 and 190 mg/dL; HDL-C ≤ 45 mg/dL (< 47 mg/dL for women); and TGs, ≤ 400 mg/dL. Patients were randomized to lovastatin (20 or 40 mg/dL) or placebo. The LDL-C target was less than 110 mg/dL. This study shows a reduction in the combined primary endpoint of MI, unstable angina, and sudden cardiac death in patients receiving lovastatin versus placebo (P < 0.001). This study also shows that lipid lowering with lovastatin can reduce CAD events in patients with average cholesterol and LDL-C levels and low HDL-C levels.
7. West of Scotland Coronary Prevention Group: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440-1445. In this subanalysis of the previously published WOSCOPS, the maximal benefit of LDL-C lowering was found to be 24%, and greater reductions in LDL-C were found to not be associated with further decreases in CAD events. Further, men receiving pravastatin had a lower risk of cardiovascular events than would be predicted based on the Framingham epidemiologic study. The authors conclude that LDL-C reduction alone does not account for the entire benefits seen with pravastatin.
8. Pedersen TR, Kjekshus J, Pyorala K, et al.: Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998, 81:333-335.
9. Plehn JF, Davis BR, Sacks FM, et al.: Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The CARE Investigators. Circulation 1999, 99:216-223.
10. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614-620.
11. Pedersen TR: Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. Am J Cardiol 1998, 82:53T-56T.
12. Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. The CARE Investigators. Circulation 1998, 98:2513-2519.
13. Stewart WJ, Hoogwerf BJ: Lipid-lowering therapy after coronary artery bypass surgery: the post-CABG trial. Cleve Clin J Med 1997, 64:347-351.
14. Goldbourt U, Brunner D, Behar S, Reicher-Reiss H: Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J 1998, 19:H42-H47.
15. Julues S: The Hypertension Optimal Treatment Study in the United States. Am J Hypertens 1996, 9:41S-44S.
16. Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials 1998, 19:314-335.
17. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605-613. After more than 4 years of treatment with conjugated equine estrogens plus medroxyprogesterone acetate in postmenopausal women with coronary heart disease, this study found no reduction in the overall rates of cardiovascular events. Because this finding is in contrast with most epidemiologic studies with estrogen alone or in combination, it has been suggested that medroxyprogesterone may have prevented the protective effect of estrogens.
18. Herrington DM, Fong J, Sempos CT, et al.: Comparison of the Heart and Estrogen/progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). Am Heart J 1998, 136:115-124.
19. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S: Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/progestin Replacement Study (HERS). The HERS Research Group. JAMA 1997, 277:1281-1286.
20. Ridker P, Kundsin R, Stampfer M, Poulin S, Hennekens C: Prospective study of Chlamydia pneumoniae lgG seropositivity and risks of future myocardial infarction. Circulation 1999, 99:1161-1164.
21. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L: Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J 1998, 19:570-577.
22. Anderson JL, Carlquist JF, Muhlestein JB, Home BD, Elmer SP: Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998, 32:35-41.
23. Pitt B, Waters D, Brown WV, et al., for the Atorvastatin versus Revascularization Treatment Investigators: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999, 341:70-76.
24. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987, 317:1237-1245.
25. Lipid Research Clinics Program: The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:351-374.
26. Coronary Drug Project Research Group: The Coronary Drug Project; clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
27. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997, 278:313-321.
28. Crouse JR, Byington RP, Hoen HM, Furberg CD: Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997, 157:1305-1310.
29. Bucher HC, Griffith LE, Guyatt GH: Effect of HMG CoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998, 128:89-95.
30. Furberg CD, Adams HP Jr, Applegate WB, et al: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events: Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994, 90:1679-1687.
31. Crouse J, Byington R, Bond M, et al.: Pravastatin, lipids, and atherosclerosis in the carotid arteris (PLAC-II). Am J Cardiol 1995, 75:455-459.
32. Salonen R, Nyyssonen K, Porkkala E, et al.: A population-based primary preventive trial of the effect of LDL-lowering on atherosclerotic progression in carotid and femoral arteries. Circulations 1995, 92:1758-1764.
33. Jukema JW, Bruschke AV, van Boven AJ, et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528-2540.